IPCALAB — earnings call
The transcript as filed. Every paragraph is addressable: its link names the page and the position it sits at in the call.
Prepared remarks
A Laboratories Limited · 3 Earnings Conference Call”
“IPCA Q3 FY ’23 F
MR. A.K
LABORA · MR. HA
MR. HA
COMPAN · LIMITED
LIMITED
Moderator · Conference Operator
MR. NIT
February 16, 2023 · K. JAIN – MANAGING DIRECTOR – IPC
K.
JAIN – MANAGING DIRECTOR – IPC
ATORIES LIMITED · Management
ARISH KAMATH – CORPORATE COUNS NY SECRETARY – IPCA LABORATORI D TIN AGARWAL – DAM CAPITAL CA
SEL AND · IES
IES
Moderator · Conference Operator
Ladies and g Conference C lines will be i after the prese signal an ope conference is I now hand th
A Laboratories Limited · 3 Earnings Conference Call”
Thanks, Mike ‘23 Earnings Labs’ Manage Counsel and C make the open
Questions and answers
A Laboratories Limited · 3 Earnings Conference Call”
Good afterno all participant Today’s earn statements ba risks that pha may differ fr information g Domestic For to INR 702 cr of around 10% business with Cardiovascula quarter.
Antim quarter, it has all three quart In spite of all last five year became, 1.76 basis, we are rank.
We wer We have five further rankin year.
Your Ze IPCA Labo Fe gentlemen, good day and welcome to the IPCA Laborato Call, hosted by DAM Capital Advisors Limited.
As a remind in the listen-only mode and there will be an opportunity for yo entation concludes.
Should you need assistance during the confe erator by pressing star then zero on your touchtone phone.
Ple being recorded. he conference over to Mr. Nitin Agarwal.
Thank you, and over to e.
Good afternoon, everyone, and a very warm welcome to IP Call, hosted by DAM Capital Advisors.
On the call today r ement are Mr. A.K.
Jain, Managing Director, and Mr. Harish K Company Secretary.
I will hand over the call to the IPCA Ma ning comments and we’ll open the floor for questions.
Please go on.
Thanks, Nitin and DAM Capital, for organizing this call.
G ts, and thanks for taking out time and joining us for Q3 FY ‘23 E ning call and discussions and answer given may include some ased on our current business expectations that must be viewed in armaceutical industry, business faces.
Our actual or future fina om what is projected and perceived.
You may take your own given during the call. rmulation business has delivered 9% growth for the quarter fro rores.
First nine months of the year, the domestic business has d %.
In segment both Rheumatoid Arthritis and Osteoarthritis co h 15% growth for the quarter. ars and Anti-diabetics segment growth has been lower at ar malarials, continuously in last three quarters, continued its dec s declined by almost around 36%, Antimalarial domestic busines ters, this business is declining by almost around 37%. that, we have continued to improve our market share in Indian rs.
In 2018, our market share was around 1.85%, '19 it beca 6%, '21 it became around 1.77%, '22 it has become 1.86%.
So e improving.
Not only improving our market share, we are al re 21st company, now we are 17th company as per IQVIA’s num e brands in Top 300 brands and all five brands in current year ng.
Zerodol-SP is 17th rank brand now with nine-rank jump erodol-P is 57th rank with six-rank jump over last year.
Hydr oratories Limited ebruary 16, 2023 ories Q3 FY ‘23 der, all participant u to ask questions erence call, please ease note that this o you, sir.
PCA Lab’s Q3 FY representing IPCA Kamath, Corporate anagement team to o ahead, sir.
Good afternoon to Earnings Call. e forward-looking n conjunction with ncial performance n judgment on the m INR 645 crores delivered a growth ontinue to lead the round 2% for the cline.
Even in this ss.
And overall for pharma market in ame 1.61%, '20, it o on a continuous lso improving our mbers. have improves its over last calendar roxychloroquine is almost around rank jump ov all five top br based on the I We have cons in Top 30 co Acute Therap Chronic segm Chronic grow the current ye further improv Most of the p published now Product pricin be announced The price red which will ha Scheduled Fo large, the imp four months i time the new too, but Q4, im Overall, our significantly That has decl Formulations is not covered On Export Br from INR 109 has been arou around 17% t market segme better growth Generic expo Institutions, th quarters of de demand of AP therefore busi IPCA Labo Fe d 132 rank with 14-rank jump over last year.
Zerodol TH is 26 er last year, and Folitrax is 284th rank with 33-rank rank jump rands have jump the ranks in the current financial year overall.
T IQVIA trade audits late December ’22. sistently outpaced the industry growth in last four years, with t ompany.
With three-rank gain over previous year, IPCA is ran pies, and one-rank gain over the Chronic segment.
Now, we a ment.
In late December ’22, we have outplacement industry i wth as per the IQVIA numbers.
With the addition of almost aro ear, we hope that we will continue to improve our penetrations ve our market share in domestic market. product where the NLEM pricings was to announce is alread w.
We expect almost around 15% reduction in the control se ng in the –whatever, we have almost around 104 SKUs on which d.
And everything is announced now. duction is in the range of around 15%.
And with almost aroun appen in April, overly, probably, for next financial year, the ov ormulation prices would be almost around 3% to 3.5%, in betw pact of these price reductions will happen only for the -- mayb in the month of February, March, then April is the going to be prices will come, from May onwards, I think overall reduction mpact would be full.
Scheduled Formulations’ contribution to the overall busines now, because one is Antimalarials, which are mostly Schedu ined.
And also because of this reduction in pricing and all.
So o are now contributing only 17% of our business.
So rest of our d in the Scheduled.
It’s all non-Scheduled Formulations. randed Formulation market, this quarter we have delivered grow 9 crores to around INR 125 crores.
For the first nine months, th und 11%, and I think for whole of the year we should be gro to 18%, the fourth quarter growth will be further significant in ent.
Market like Latin America, Middle East, Africa, Southeast A for the quarter.
[SEAs 0:07:02] has delivered around 11% grow ort business including Institutions has delivered 14% growt he growth in Generic business has been around 6% for the quar ecline, because of various issues which were facing, industry PI, price reduction, nitrosamine impurities, azido impurities, al iness of active pharma Ingredients has declined in first two quar oratories Limited ebruary 16, 2023 64th rank with 38- over last year.
So These numbers are the highest growth nked now 13th in are ranked 18th in in both acute and ound 1,500 reps in in the market and dy announced and egment Scheduled h the prices was to nd 12% price rise, verall reduction in ween.
And by and be around three to the major.
By the n will come down s has gone down uled Formulations. overall, Scheduled r product portfolio wth of around 17% he business growth wing in excess of n the Promotional Asia has delivered wth for the quarter. th, and excluding ter.
After first two was facing lower ll these issues, and rters.
API business, to INR 322 cr around 7% fro get covered in may not be a also.
It’s just impurities or since have pa This quarter, in third quarte cost rise was issues and hig And KSM pr holding, becau margin in tim short-term iss For the first n higher than 33 margin in com crores for the Apart from b cost in the po around 1,500 financial year Our fourth qu that much bet and API bus quarter may reductions, w next financial Having given
Moderator · Conference Operator
We have the f
A Laboratories Limited · 3 Earnings Conference Call”
The first ques have said we baked into Qu
Yes, that num vacancies, but IPCA Labo Fe , this quarter, has delivered around 4% growth to around -- fro rores.
For the first nine months of the current year, the busines om INR 1,084 crores to around INR 1,004 crores.
But most of t n the fourth quarter of the current financial year.
We hope th any decline in the API business in the current year.
There may t going to be a marginal site.
And although ongoing issues azido impurities and all which the regulators were facing, all tho ssed.
There are no issues left of that nature now. material cost to total income ratio has come to around 34.13% er in last financial year, an increase of almost around 1.67%.
L there, mostly in the solvents or maybe aluminum foil, but ongoi gher cost inputs got converted at lower API prices.
That has resu rice trends are also towards decline and therefore whatever use of the price reduction, this impact is there, but we don’t fore me to come, we will be able to go back.
Gross margin is not a con sue. nine months of current year, our material cost ratio is around 33 3% in last financial year.
The price softening trend, we hope to ming quarter.
The other expenses include forex loss of almos quarter as compared to a gain of around INR 10 crores in last fi e above, other expenditures has largely gone up because of h ost-COVID era.
And large addition of medical representative ad is also contributing to the higher cost.
With their becoming p r, we hope that this ratio will also get corrected. uarter growth is expected to be almost around 10% to 12% ran tter growth will come from Branded Promotional market.
Gen iness, all three will contribute better growth.
EBITDA marg get further impacted due to the change in the Scheduled hich will get some impact during the fourth of the year.
But we l year, our margins will certainly improve. the broad numbers and guidelines, I request now, participants, t first question from the line of Kunal Dhamesha from Macquarie stion is on the MR additional.
I think till last quarter, we were will add 1,500.
So are we done with that addition?
Is the increm uarter 3 number? mber is done now.
Almost around 1,500 people are added. t broadly it’s done now. oratories Limited ebruary 16, 2023 m INR 310 crores ss has declined by these declines will hat probably, there y not be a growth s like nitrosamine ose issues are now as against 32.46% Largely the inputs ing China COVID ulted. r KSMs we were esee that our gross ncern for us.
It’s a 3.88%, marginally improve our gross st around INR 16 inancial year. higher promotional dditions of almost productive in next ge, and we expect neric formulations gin for the fourth pricing and price e are confident that to ask questions. e. at 1,200.
Now we mental cost already There are certain
And sir, if tha Because I bel allowances w
Last financial 28%, 29%.
A much, much a incentive.
An payments are appearing tha on higher side
And secondly around 650 ba of provide som impact that is increase, whi over the next
Number one second head h come in the increase.
Mat by and large, business outfl nitrosamine, compared to t So practically has also depre many, in fact, to be soft, and Personnel cos resulted 0.72% As far as man side, as again increase in m years during energy cost c almost around other coal fur Analytical co nitrosamine t IPCA Labo Fe at is done, then why we are not able to see the jump in the em lieve the fixed salaries, it would be part of employee expense ill be part of other expenses… l year, our business growth in domestic was significant high And therefore our incentive payment last year was very, very above normal incentive because from incremental sales, people nd this year, the overall growth numbers are lower and th e also lower.
And that is offsetting the increase in the cost at overall manpower cost has gone up by 13%, but in fact, exclud e. y, if I look at on a nine-month basis, our margins have kind asis point.
That excludes any forex loss or gain from both the ye me kind of clarity in terms of what are the major drivers, one b already baked in into these nine months?
Similarly, let’s say, po ch are the major drivers of this 650 bps, and which of them year? was material cost.
Practically, it’s around 1%.
It has gone u has been the personnel costs, which has moved by 0.72%.
The m manufacturing as our expenses, which is almost around 4%. terial cost front, we are not worried now because overall, there all the old KSM inventories which were weight more particular lows, and particularly also the certain inventory which got stu which was at -- their procurement price of KSM was mu the current prices. y, 17%, 18% higher prices.
That has also not only increased th essed the margin because KSM prices have come down.
So tha , KSM price.
And KSM prices are soft.
So overall, material co d I think overall margins will improve. st is higher because the numbers have moved up in current y % kind of overall increase in personnel costs. nufacturing and other expenditures are concerned, by and large nst our growth of, let’s say, around 9%, 10% overall increase is manufacturing side.
Largely, the power tariffs were not increa COVID times.
So most of State boards have increased the p continue to remain very high.
I think, overall energy cost nu d 45% for current year.
So, that has been very high, because th nace foil and all that we buy for energy, that has been at a very, ost has also moved significantly, because now lot of batches n tests and so many other tests are introduced there.
So, oratories Limited ebruary 16, 2023 mployee expenses? es, right?
And the her, almost around y high.
It was the e get much higher herefore incentive t.
So overall, it’s ding incentive, it’s of compressed by ears.
Can you kind being the MR cost ower and fuel cost you see reversing up by 0.89%.
The major increase has So, that is major is a softening and rly in API and API uck up because of uch, much higher he material cost, it at has happened in ost ratios are going year, and that has on manufacturing around 13% is the asing for last two power tariffs.
The umber increase is he all the coal and very high level. need to be test for testing cost has significantly, particularly fo work also nee 0:17:02].
So, Then, travel c was very, ver down.
Then promotional c year.
So that is a m wanted to do in last two, promotional c With the prod down.
Energy product cost there’ll be red softening and
And would y improvement
I think it coul
Moderator · Conference Operator
We have the n
A Laboratories Limited · 3 Earnings Conference Call”
Sir, in terms already or som
I think most o late Decembe started getting have almost 1 prices are ann So, all those numbers.
It’s reductions is t this, 12%, as overall impac four months, we’ll be able IPCA Labo Fe plus this year also, lot of work has been to reestablish th or all those kind of testing.
And since lot of work has at the sa ed to be given outside because everything cannot be done in-hou even that cost has been high. costs mostly doubled.
That’s another cost.
Shipping costs, in ry high, but from third quarter onwards, the shipping costs ha it’s a promotional costs.
The major impact during the ye costs.
And practically, that has moved up by almost around 5 major impact, is also addition of the people and also various ac as a company on various therapy areas and all that.
Those acti three years, and lot of those activities was done.
And bec cost is on a higher side.
And that is the major contributing factor ductivity additions and with people becoming productive, thes y costs, we are not seeing much of trend in further reduction comes down little bit, then probably that cost may come d duction in the cost, because of higher productivity additions and d all that.
So with that, the margins will improve. you be comfortable providing any broad range in terms of for next year? d be remain in the range of around 21%. next question from the line of Cyndrella Carvalho from JM Fina of the NLEM impact that you’ve mentioned, have we taken me of it will flow in Q4 as well? of the impact is going to come in Q4, because price enhancem er.
And so December impact is, I will say that very marginal. g announce in early December, and then, I think it has now com 104 SKUs, which are in price control.
All product prices are a nounced yesterday only. price announcement, I would say, I can give the number now. around INR 70 crores reduction on annual basis as far as NLEM there.
And it’s working out to be around 15% of the NLEM pro I already said that around 12%, we will get the wholesale p ct will be 3%, 3.5%, not more than that.
And that too, it will re because we are now keeping very low inventories of products to do a faster implementation. oratories Limited ebruary 16, 2023 he methods, more ame time, so lot of use at a [inaudible first two quarters ve started coming ear has been the 0% in the current ctivities which we ivity was not there cause of that, the r for this. se costs will come , but if petroleum own.
But overall, d also material cost EBITDA margin ancials. n it in this quarter ment started late, in Most prices have mpleted.
I think we announced.
10, 12 .
We have got the M portfolios price oduct sales.
Out of price increase.
So emain for three to and so, hopefully So it’s only months in wh has also come control.
Our contributions overall, 83% going to be m
Sir, in Q4, we
Yes, Q4 will product would
And sir, we’v crores number
That INR 70 little more als notes.
And w when the pric other things. fourth quarter
And sir, if we But are there growth?
The Cardiova numbers are having jump months is onl number is low Antimalarials year has decl COVID issue nine months, 10 crores dec that is buildin Our CNS bus business, we h by around 13 Neuro therapi IPCA Labo Fe going to be say your January, February, March and April, t hich the impact would be there.
And thereafter the -- and our N e down.
Now, it’s only 17%, whereas largely Antimalarials are i Antimalarial business has gone down.
And with that, to the overall, say, business is only at around 17% now as on of our portfolio is out of price control, I would say.
And so marginal now. e’ll see some impact on the overall gross margin because of this? be the highest impact.
Because Q4 will be all 15% kind of d be there. ve not building any [inaudible 0:21:31], because of the price c r that we are seeing, right? crores is for full year.
I’m taking full-year basis.
And in Q4, th so because of the trade inventories in the market also.
Trade w we will have to give them credit notes.
So we are in process o ces are announcing, all these fields are verifying all the stocki And all those credit note business will also be there in the f r impact would be greater for industry. e look at our India domestic business, our Zerodol franchise con any other segments or specific therapies which are kind of imp ascular business, which we want to grow fastest.
In fact, a concerned, they’re looking at that, we are, in fact, in Chronic of one-rank, but our overall growth in Cardiovascular segme ly around 4%.
So, it’s a low number.
We expect it to grow mu wer. has declined by around 37%.
But our other segments like, and lined by -- because last year, we had almost around 100% g es and others.
On that, there is a very marginal decline, on Ant we did a business of INR 134 crores as against INR 143 crore cline.
So it’s not significant in spite 100% growth in last finan ng base for our future growth also in Antibacterials. siness is growing by around 18%.
Cough and Cold, despite last have growth of around 10%.
Derma is growing by around 18%.
3%.
Ophthalmology portfolio is around 17% kind of growth. ies are also doing very well for us, yes. oratories Limited ebruary 16, 2023 these are the four LEM contribution in big way in price overall, NLEM n January-end.
So those impacts are ? impact on NLEM cut in the INR 70 he impact maybe a will ask for credit f verifying as and ist inventories and fourth quarter.
So ntinues to do well. pacted our overall as far as industry c segment, we are ent in current nine uch faster.
So that d Antibacterial this growth because of tibacterials in first es.
So around INR ncial year.
In fact, t year’s significant Neuro is growing So by and large,
And sir, on th what is our str
As far as this whatever wor have added tw In fact, the on because docto reason for low in Cardiovasc time to come
Moderator · Conference Operator
We have the n
A Laboratories Limited · 3 Earnings Conference Call”
Sir, for the do done well.
So domestic busi
I’ll give you t
Yes, Dheeraj, and Anti-diab growing at 4%
But you’re sa Because you Neuro, Derma
17%, 18%.
So sir, what a market would
In fact, we ha in the opening now become compared to m
So why is the
It’s only beca because the p Whenever the is the year wh all that.
So the IPCA Labo Fe he Cardio, Diabetes, even the segment is also not improving a rategy here?
What are we trying to play to gain higher share and segment is concerned, now we have very good recognitions at rk we have done in the last few years on our CTD range and ot wo more divisions in Cardiovasculars in current financial year. ne of the reasons for little lower growth is also because of the a or-product relationships and all get disturbed and all that.
So wer growth that is around 4%.
But with addition of these two m cular and the addition of products, we will certainly have a much in Cardiovascular. next question the line of Dheeresh Pathak from White Oak Capi omestic business, the Cardio and Diabetes and the Antimalaria o for the full year last year, FY ‘22, what would have been iness for these two therapies? the number, just a minute. , Antimalaria last year was 5% of my domestic business, and t betes was 17%.
So both put together around 22%.
Out of that %, only that 5% portfolio of Antimalarial, they are de-growing a aying ex of this, the balance 78% of the portfolio is growing at said Pain and Rheumatoid is growing at 14%, 15% and then a, everything going at mid to high- teens? es.
So other therapies are growing definitely anywhere between are we doing to increase the growth?
Because Cardio and Diab d not have grown at 4%, right?
Have you lost market share?
Wha ave increased.
In fact, our rank has jump in cardiovascular side. g remarks as far as on Chronic segment, overall, our rank has 18th company in Chronic segment.
We were 19th earlier a market, we have done better and compared to… market only growing at 4% in those molecules? ause of [divisionalization 0:27:14] in current year, certain low product reshuffle has happened.
So with that, all those mark ere is a realignment in business and all that, some disturbance here we have added two more cardiac divisions and reshuffled ere is a suffering on that account, yes. oratories Limited ebruary 16, 2023 as highlighting, so d faster growth? t marketplace with ther range, and we addition of people o that is also one marketing divisions h higher growth in ital. al portfolio has not n the sales in the the Cardiovascular t, 17% portfolio is at around 35%. t mid-teens, right? you listed Opthal, 12% to 20%. betes, that covered at is in this… That’s what I said also jumped.
I’ve a year earlier.
So wer end products, kets get disturbed. happens.
And this d the products and
No. Sir, you h Cardio and D What has hap
Market overa stocks.
The pe many people w on a normal p Second factor so many medi which becaus significant am So post-COV we have neve years.
This m market itself h
Which are the
We have pres we have, we h
Metformin, th
For which, we portfolios.
An
And in cardio
On cardio sid newer molecu
And sir, last q
Yes.
That’s w
Moderator · Conference Operator
We have the n
A Laboratories Limited · 3 Earnings Conference Call”
Sir, I have tw of API prices API, so ex AP sequentially?
If you exclude IPCA Labo Fe have anyway grown better than the market.
I’m saying, why is th Diabetic portfolio is not growing more than 4%?
You’ve done ppened to the market overall? all, there is probably in Chronic segment, people were keepi eople buying because of COVID times and all six-month stock were buying that way.
So those demand has now is normalized. pattern.
So that could be one factor. r also could be that a lot of the people who are in old age and a icines, they’ve also disappeared from the market.
So that’s also se a lot of old people have died, which were using a lot of card mount of cardiovascular drugs.
VID also, that also may be one of the impact could be there in thi er seen this kind of growth in Cardiovasculars and Antidiabeti market has been significantly moving up.
It’s only the curre has not done that well. e main molecules that were presented in Cardio and Diabetes? sence on diabetes all the main kind of molecule like, we have have are all these newer drug… he newer ones also you have HBMC-2 and BPC-4? e’re not marketing as an individual single drug, but we have the nd like gliclazide we have, glimepiride we have Vildagliptin we o? de, we are on beta blockers, and we are also there on chlorthalid ules whatever has come in the market, we have introduced at the question, could you say the 21% EBITDA margin for FY ‘24? what I told, yes. next question from the line of Amit Kadam from Canara Robeco wo questions.
One thing is in an opening commentary you menti s, my gross margin had impact.
So just wanted to understand, PI, our gross margins would have been better or has it done be e API business, definitely, yes. oratories Limited ebruary 16, 2023 he market in those e internally, right? ing, one is higher to one-year stock, .
So now buying is all that and taking maybe one factor, diovascular drugs, is market, because ics for last 15, 20 ent year that your sulfonamide urea ese newer product have, yes. done.
And now the e same time. o Mutual Fund. ioned that because ex that particular etter in the at least
And then just basket, how o ROWs?
And going forward
I would only had 11% grow much better.
A be growing ar around 15% t markets, we a that are not th As far as your 300 crores to almost around think the insti overall, Institu between INR Institutional G
Sir, in the AP has that stopp
No, prices no the trend has g seeing now f prices further also start mov
But how the settled?
Most, I think the API busin fourth quarter recovery in th decline in AP are looking fo So probably t 1,311 crores k API business regulators we that needed to product and a IPCA Labo Fe t wanted to understand how the – like, now the prices are fo our export numbers are looking forward, especially like the reg then just your early commentary on how we need to look at th d in FY ‘24? say that your ROW markets, we are doing well.
I think for firs wth.
This quarter, we had delivered 17% growth.
Fourth quar And overall, I think branded promotional market for the whole round -- in the fourth quarter is going to be significant.
The gro to 16% for the whole of the year for in the Branded Promotiona are doing better now.
All these issues of whatever COVID rela here. r Institutional business is concerned, probably it’s going to be in something plus.
We expect one more product approval that cou d INR 50 crores, INR 60 crores addition in the business.
But w itutions may reduce the buying of your KL.
That’s what we are l utional business, I’m not giving much bigger number.
I think ov 325 crores to INR 350 crores, that’s the kind of number could Generic business.
PI business, has the drawdown in terms of like the price coming ped? ow, there is no as such dropping has already happened.
Because gone down, that has with that even prices dropped.
Already hap further decrease in overall in the prices.
And we are also not r going down.
With that only now, with the demand picking up ving in next year, a little bit.
And API prices will also move in li market has behaved in last few months, just to understand w API players had poor businesses in first two quarters.
We als ness in first two quarters.
This quarter, we have done better, arou r, we are looking at much better growth.
Overall, I think w he API business in fourth quarter.
Currently, we are at around PI business.
I think that may entirely get covered in fourth quarte or. there may not be a growth.
We may be at last year, we did al kind of business.
We may be more or less at the same numbe es.
Good ground will be getting covered.
And all those issu ere looking for, azido, nitrosamine impurities in all those produ o be tested for all that and revised method needs to be worked all that.
You’re all filing in various markets on that.
All those wo oratories Limited ebruary 16, 2023 or the overall API gions like UK, the he tender business st nine months, we rter is going to be of the year would owth may come to al market.
In most ated issues and all n the range of INR uld have a scope of with that addition, I looking at.
And so verall, may remain d be there in your or going down, so e whatever KSM's, ppened.
We are not t seeing the KSM p, KSM prices will ine with that. where it’s getting o had a decline in und 4% growth.
In e will have some d 7%, 8% kind of er.
That’s what we lmost around INR er, more or less in ues which are that ucts, every product d out to test every orks are now done.
So there are n the developed inventories al that.
So proba
Sir, next yea geographies w that organic g
Yes, the expa around 11 to around two or filings will s Thereafter, th month stabilit Some of the year, some, a start getting a projections, w some of those because there licenses and developed ma
Moderator · Conference Operator
We have the n
A Laboratories Limited · 3 Earnings Conference Call”
Sir, if you can or what more few more qua
I think most quarter, I thin where I think price may be since the proc 0:38:18] in th around $180.
So that’s only months, I wou quarter.
And sir, if y period?
Or dir IPCA Labo Fe no those disturbing factors, and all those excess inventories in th d markets were definitely carrying higher, higher inventories o lso of the generics.
So those also, inventories have now getting ably API business will also have a good recovery in the next fina ar, in FY ’24, on this particular base, any new product la will be, because we have an expanded capacity available so on growth to Q2? anded capacity, by and large, what’s happening, we have, I thin o 12 product validations at Dewas.
And each product valida r three months’ time.
So most of the time, we’ll be going and f tart somewhere in, I think, in early next year, beginning, fi he inspection should happen of that plant.
So because for a filin ty and then your dossier compilations and then filing. regulators may come early, some regulators may come late.
S at least a few inspections should start happening from of that si approval.
Post that, the business would increase.
So right now, we are not adding any kind of business increase coming from De e kind of production may happen and we may sell in domesti e, you will not need any kind of approvals all those approvals ar other things.
Even GMPs are in place.
So that’s not an issue arket business will only start after the inspection of the plant. next question line of Surya Patra from Phillip Capital. n give us an understanding whether the high cost inventory is li e period?
So whether it will be depleted in the coming quarter arters to deplete so that some sense on the margin front that we w of the inventories are now depleted.
It’s only a matter of, let nk will -- some more will go.
But except one particular KSM, compared to the market, I think current pricing, my overall pro around $30 to $40 higher because we were the early one to curement and did not happen so prices has -- it’s more particula hat prices have dropped to around $140 or so.
My average y the KSM where it may have some impact for the next six, uld say.
But all others have normalized, will normalize in this you can give some sense about the promotional spend during rectionally, how much that it would have gone up versus last ye oratories Limited ebruary 16, 2023 he market, because of API and higher g depleted and all ancial year. aunches and new n that, can we see nk, lined up almost ations take almost filing.
And I think iling should start. ng unit to have six So hopefully, next ite, and we should we are not in our ewas plant because ic markets and all e already in place, e at all.
But your ikely to sustain for or if it will take a will have? t’s say, for fourth , of Antimalarials, ocurement average do the tie-up and arly for [inaudible holding maybe at eight months, six quarter.
Yes, next g this nine-month ar?
I think almos less, these nu the promotion people added, has not added margin.
Yes.
Sir, about the had filed, so,
No, we are ba issues, Surya.
All approvals
Everything is
Sir, you have we have not intermediate s
Nagpur, I thi environment Department a that the forest Delhi has acc any kind of f that much kilo but it has tak approval, so t So it took a l projects, whic we were to t ordered.
So th the next fina basically draw
Sir, just last o much higher building on th
See, the tax r now because disallowances additional tax IPCA Labo Fe st it’s around 40%, 45% that has moved up compared to last y mbers would remain at same level in next year.
So with increa nal costs will not go up.
And that will add to the margins now. , there also, the marketing cost or promotional costs have gone u d to the productivity to that an extent.
So that will also hel revised or the new process about the sartan the after the impuri any update on that?
So have we started seeing some recovery? ack on normal business, both Valsartan as well as Losartan.
The . are received. in place.
There is no issue. provided some update about the Dewas.
But if you, means, sir t heard about the Nagpur site, which was expected to a site.
So if you can give some sense about it? nk two months back, we have got the final clearance from th side, because they have put earlier one condition that you nee approval.
And it took almost around one, 1.5 years’ time to repr t clearance is not required for this site, which finally the Enviro cepted the Maharashtra Government’s recommendation that this forest clearance, because there are certain parameters defined t ometers from all these wildlife and everything.
So it doesn’t fal ken almost around very long time because forest is a multi, m they’re most stringent approval. ong time.
And finally, we got.
We are working on some kind ch will be put at Nagpur.
But because of these delay, one particu transfer to Nagpur that we are putting at Aurangabad.
So tha hat is not going at your Nagpur, it is going at Aurangabad.
Pro ancial year, something would happen on that.
So right now wing board stage, not finalize any kind of capex on that front rig one question.
So this tax rate that we have guided, so I think we than the indicated tax rate levels for the current year.
So h hat for next year? rate now from 18% has moved to 25% because our opting for e of all these judgment of Supreme Court and also last bu s all the promotional costs.
So that is adding almost around 3 x.
So tax rate is likely to be in the range of around 29% to 30% k oratories Limited ebruary 16, 2023 year.
And more or se in the business, And a lot of these up.
But whereas it lp in building the ities issue that you ere are no pending r, since some time, kind of KSM or he government on ed to get a Forest resent and see to it onment Ministry in s site doesn’t need that it has to be in ll in that category, multilayer kind of of flow chemistry ular product which at plant is already obably, it’s only in , we are only at, ght now. e are currently at a how should we be that method.
And udget revision or 3% to 4% kind of kind of rate.
Moderator · Conference Operator
We have the n
A Laboratories Limited · 3 Earnings Conference Call”
Sir, this testin also?
And is i
It is not only f I don’t think g
See, nitrosam Antimalarials to be tested.
A somewhere 15 It may not be It can come fr done and see It’s a huge am formulations, So that was a
But sir, if it co
Yes, so, testin
But initial tes Once it becom
Because when product, final components a in the range o
Sure, sir.
And
Establishing t
And I assume
Yes, everybod
And sir, mayb maybe some a
Like I said, a API business We are growi addition of pe IPCA Labo Fe next question line of Kunal R. from Nuvama. ng cost of the APIs that you spoke of, is it restrictive to sartans it an ongoing expense? for sartan, most of the other APIs also.
And more or less, that co going forward, there would be anything of that nature. mine is one kind of thing, which is to be tested for all AP and everything, all generics, all your formulations and all API And it’s in parts per billion.
Somewhere it’s maybe around 3 5 part per billion.
So everything has to be done.
And it can com there in your product, but it may come from water, it may com rom any kind of excipients which is being used.
So a lot of vali to it and all these numbers have to be filed with regulator. mount of work industry has done in last financial year.
On A excipients, everywhere it needs to be tested because all the new very, very tough work, which industry has done in last year.
It’s omes from water also, that means it has to be an ongoing thing, ngs are going to be ongoing…. ting, method validation, development, that takes a lot of time an mes a routine part of your process of testing, then there is not mu n you establish, so many components you need to test.
But o lly everything is okay, then only our final product testing bec and all 10 components need to be tested.
But suppose in final pr or lower than that range, then subsequently, it’s only one test. d sir, maybe some aspiration guidance… the method of testing, method of -- is a very big subject, and the e, all the manufacturers would be going have been testing… dy has done that.
Everybody, every formulation, it’s a big, big e be some on a slightly longer term, maybe a two or a three-yea aspiration guidance for generic export and API, you would like t s we have already talked that we are already talking that from should double.
Formulations, we are continuously doing very w ing around 1.5x the market growth.
And with that, and domestic eople and all, it should continuously add to the market share. oratories Limited ebruary 16, 2023 s or other products ost is now already, PIs, including our s, everything need 5 part per billion, me from anywhere. me from anywhere. dations need to be API, intermediates, w standards are set. s a big, big… right?
Because… nd a lot of money. uch issue. once you are final cause there are 10 roduct, it’s coming n validating that. exercise, yes. ar kind of outlook, to share? here onwards, our well in the market. c because with the In the last fou continue to do market busine around 15% t So overall, th guidelines wh around the tim the guidance f
And just as on maybe would ones?
Even in the e well as volum
Plus capacity
So I assume d
It is not record
Moderator · Conference Operator
We have the n
Nikhil
Two question KSM prices business has fallen, but the too much.
A Laboratories Limited · 3 Earnings Conference Call”
That is right, y
Nikhil
So if we look prices and eve
A Laboratories Limited · 3 Earnings Conference Call”
No, not in the higher prices, on for last two the next finan
Nikhil
So the net pro
A Laboratories Limited · 3 Earnings Conference Call”
I mean to say
Nikhil
And this 12% which the wh IPCA Labo Fe ur years, we have had a significant market share from 1.58% to o that.
And the first time I think in current year, we will be cross ess of around INR 500 crores.
And at that level, we should o 16%, 17% on ROW market business. he growth in time to come is going to be good.
But overall, hen our overall budget for the current financial year is finaliz me first quarter results and all, our annual results.
Around that t for the next financial year. ne follow-up to this.
If you talk of API doubling, what would b d it be new products?
Or do you believe there is a lot of head existing product, there is a lot of headroom.
So it will be both me growth in the existing products. additions and new product… demand is not a concern for you.
It’s just… ded, no. next question from the line of Nikhil from SIMPL. ns.
Sir, like last quarter, and this was an industry phenomenon were high but the API prices has fallen.
As a result, the pr been impacted.
Now, during the call, you mentioned that the ey are not falling anymore.
And the KSM prices have also fall yes. k at the profitability of the API business, based on the correc erything, are we back to the normal profitability or is it…. e third quarter.
See what has happened, actually, whatever KSM , they got converted into API, which got sold at a lower price. o to three quarters.
Maybe some pain will be there in the fourth ncial year, first quarter onwards, everything should be back to no ofitability on API should be back to what it was in… that the gross margin on API business will improve. % price increase on the NLEM which we mentioned is the W ole industry will take? oratories Limited ebruary 16, 2023 1.86%.
So we will sing, I think ROW continue to grow we will give the zed and maybe at time, we will give be the main driver, droom for existing h, new products as n in API, that the rofitability in API e API prices have len, but not falling ction in the KSM M we purchased at So that was going h quarter.
But from ormal.
WPI price increase,
A Laboratories Limited · 3 Earnings Conference Call”
Yes.
Nikhil
And last ques significant.
So kind of EBIT increases and worst quarter.
Do you think freight and po 24%, 25% on maintain that
A Laboratories Limited · 3 Earnings Conference Call”
See, last two margins were year, there is increase in the So these two business will negative is th productive, ev also become n
No, so, curre business.
It w depreciations to P&L accou So it’s a one- getting debite adding to the
Nikhil
And last thing would just loo
A Laboratories Limited · 3 Earnings Conference Call”
INR 200 cror the total capex
Only new thin where we hav year.
We hav now.
So we ar
Nikhil
This INR 500
A Laboratories Limited · 3 Earnings Conference Call”
Yes.
IPCA Labo Fe stion, sir, like if we look at last 1.5 years for IPCA, the cost p o prior to, like in around second half of ’21 and all, we were clo TDA margin.
And then there was a high freight cost and t d the testing increases, all of that has impacted very badly and . k from here on, with the cost pressures and everything gettin ower cost and everything can we come back to what we wer n a longer period, not in next two, three years, but is the bus 24%, 25% or do you think it could be a difficult task? o years, there were also benefit of COVID business, correct? e very, very good.
But having said this, now Mr. Jain has alread s an unusual, one is increasing the people, expenses, energy e material cost, correct? things are taking away around 5% to 6% of my margin.
As grow because of addition of the people.
This material cost, wh here, it will become positive going forward.
And as the pe ven the other expenses portion where we are today 4% increase normalized.
So going forward, definitely, margins should impro ent year, even Dewas plant all costs are debited to P&L acco will -- all cost only because till the time we start filing and and all your people cost, testing costs, all the energy cost, eve unt, and there are no top line coming from that plant.
So it’s only -year 1.5 years, that pain is there in pharma industry everywhe ed to P&L.
It’s not only people costs, it’s also the plant and ca overheads. g, what would be capex guidance for next year, ’24-’25?
Any ok at utilize, improving the utilization… es is our depreciation and maybe INR 400 crores to INR 500 c x, including routine maintenance capex. ng what we have budget we have is a biotech project which is c ve around INR 150 crores kind of investment.
So that will be c ve almost around five products in pipeline now, two around ar re building the capacity for biotech projects.
0 crores was cumulative for two years? oratories Limited ebruary 16, 2023 pressures were too ose to a 24%, 25% hen the API cost this quarter was a ng normalizing on e doing at around siness still able to ?
Because of that, dy explained.
This y cost as well as we progress, our hatever, 1.5%, 2% ople will become e is there, that will ve. ount, there are no getting approval, erything is debited y validation mode. ere.
So that is also apacity cost is also large capex or we crores level will be coming up in MP, ommissioned next re in clinical stage
No, it is each
Moderator · Conference Operator
We have the n
A Laboratories Limited · 3 Earnings Conference Call”
Sir, just exten on…
Moderator · Conference Operator
Sorry to interr closer to the m
A Laboratories Limited · 3 Earnings Conference Call”
I will come ba
Moderator · Conference Operator
We have the n
A Laboratories Limited · 3 Earnings Conference Call”
Sir, on this fo reason for thi this operation
By and large, have assets in forwards, the realized gain around INR 3 If you look at of INR 10.73 books, and fo So INR 21 cro against the im bills, but on realizations.
S on loans acco
But sir, on th the higher exc
That’s what I crores.
And o crores is on ac same level is loss booked in that when the
Sir, on this di three quarters over?
Because IPCA Labo Fe year. next question from the line of Tushar M. from Motilal Oswal. nding this discussion on this biotech.
So what sort of project rupt, Tushar, your audio is not very clear.
If you go off the spea mic? ack in the queue, maybe. next question from the line of Dheeresh Pathak WhiteOak Capit orex loss and gain that we show, what is the underlying nature o is?
Can you just explain like which currency is it linked to and n linked to?
What is it? , all these forward contracts, we have today not much of forex n terms of bills outstanding and all that.
So your realizations at readjustment is all debited to P&L account.
If you look at curr of -- realized loss is around INR 6.68 crores, unrealized loss bo 35.22 crores.
And overall net loss because of forex is around INR t other breakup of that INR 41.9 crores, there’s that INR 21 cror 3 crores is on account of packing credits outstanding which we oreign currency loans, your ECBs is around INR 10.3 crores. ores is on account of loans.
And INR 20.86 crores is on account mport of material on outstanding payments and by and large bet forward side, there is a loss of INR 48.84 crores and INR 40 So overall, INR 21 crores on trade account.
And around INR 21 ount, that’s more breakup. he asset side also, we’ll be benefiting, right?
Because the realiz change rate in the revenue line item, right?
I said, the realization higher is INR 40 crores and forward gain n import side, there are around INR 10 crores loss.
So overall, i ccount of your business transaction.
Around INR 21 crores is m on account of outstanding loans.
Realized loss is INR 6.68 c n books is around INR 35.22 crores.
And we don’t create a rese contract gets matured and we debit instantly to the P&L accoun id Artemisinin, did you say that you will still have loss on the s, we’ve been having this, right?
So why is it not running, wh e how much inventory do you carry off the KSMS and for Artem oratories Limited ebruary 16, 2023 ts are we working akerphone or come tal. f the -- underlying d which market is x liability, but we t lower prices and rent year, we have ooked in account is R 41.9 crores. res is only account ere repriced in the t of your balances, tter realizations on 0 crores is higher 1 crores is broadly zation will book at loss is INR 48.84 it’s around INR 21 more or less around crores.
Unrealized erve kind of things nt. -- so for last two, hy is it not rolling misinin?
Artemisinin, n you sign con contract for t inventory at h every invento to do the cont
This particula is $140 to $80
This year bec gone down.
T with them bec comes from C
No, sir, if eve
I’m the larges
What happen down.
So opp would be pri matter as far a business, yes, market price a
And sir, apart
No, there are
No KSMs of t
No. Like you has come dow
No. That is w now.
See, from carry invento API, that is w
Plus these all $9, it was dou months, all th disposed off.
Moderator · Conference Operator
We have the n IPCA Labo Fe normally, it’s a seasonal product.
So normally, you don’t carry ntracts, though it’s seasonal.
It comes in the agri season, yo the entire year.
So, your contracts are at higher price, not that higher price.
So those contracts you have to honor.
It’s not th ory in pipeline, because when your agri output comes, around th tracts. ar product, as you know, the price varies.
It is an agricultural co 00, just imagine the fluctuation in the price of this commodity. cause of tenders there was lower procurement from the authori There are only three, four manufacturers and your contract ha cause they are all WHO prequalified, again, suppliers of artem China.
95% of that comes from China, and only three, four manu erybody is having the same higher cost of agri… st consumer, that is the issue.
Unless I… ns that, suppose your procurement price and now open market portunity to procure at a lower level is -- suppose you are se cing those API sales at the current price, current artemisinin as your Antimalarial formulation business is concerned.
But wh , it matters because we will do the pricing based on not my proc and then same price.
Further, I’ll not be able to sell APIs. t from artemisinin, the other KSMs you carry for like three mont no other KSMs. that nature is there. said, you’re explaining that we are carrying higher priced KSM wn, that is affecting the API gross margin. what happened till Q3 end, as we speak now, there are not m m procurement to utilization, there is a time gap, because every ory.
We are backward integrated.
So, right from intermediate why our inventory of KSM in few material is higher than average sartan inventories were stuck up, which was at much, much hi uble the rate earlier.
So my procurement of those which -- bec hese issues, approvals and all that a lot of those inventories That’s the major issue. next question from the line Saion Mukherjee from Nomura Secu oratories Limited ebruary 16, 2023 the inventory, but ou need to do the t you are carrying at we are keeping hat time, you need ommodity.
History ty.
So prices have as to be with only misinin.
Everything ufacturers. t prices have gone elling API, market n price.
It doesn’t hen you do the API urement price, but ths?
M and the API cost any KSM left out y stage you have to e, we manufacture e. igher price.
See at cause of six, eight s are now getting urities.
A Laboratories Limited · 3 Earnings Conference Call”
Sir, on EBITD FDA issues h come down, a three, five-yea you think wou
I think from expansion wil margins from
Sir, you mad control or the annual incom products with that?
1 April, yes.
There’s visibi
Yes.
That’s th
So whatever simple.
There’s no am
No, there is n
And sir, on interactions o there, and wh
From our side we are in dial
So, your GM anything furth when they sch when they wi are certainly they don’t ne things of past It’s only, they department.
T IPCA Labo Fe DA margin, so there has been a lot of volatility in the past.
I m happened, we were at early 20s.
Of course, it went up last ye and you’re guiding for 21% next year.
What’s your assessment ar perspective, where do you see as the business normalizes, the uld sort of settle at? next year onwards, for the next three years, I would see th ll happen in field for size.
And therefore, and businesses will im m that level will further keep on rising, maybe around 1% every y e a comment around the NLEM 100-odd SKUS which have e prices were revised, right?
So since the revisions just happen me impact of INR 70 crores, this WPI increases would be hin a few months?
I mean this will get negated?
I mean is th ility on that, okay. he visibility for that, Yes.
It’s…. price on 31, March, whichever product, you can increase to mbiguity. o ambiguity.
US FDA, we haven’t heard much.
So I’m just wondering on why the FDA is, I mean, where are we on the remediation hy we are not seeing much progress on… e, remediation work, everything is complete.
We are just awaiti logue with….
MP inspections, GMP has given in writing that we are nothin her from you, and we have responded to the inspection team hedule, it’s another team, which we are regularly taking, but t ill come for inspection.
So they have their own priorities and su in the -- because now there is absolutely, nothing is asked by eed anything from our side as far as remediation part, and al . y need to now schedule the inspection, that’s all.
That’s not d That’s done by the inspection department.
So we are in touch w oratories Limited ebruary 16, 2023 ean before the US ar and now it has t from a, let’s say, e EBITDA margin hat not significant mprove.
So overall year or so. come under price ned and there’s an allowed in these ere a visibility on o that extent.
It is if you have any and any progress ng inspection, and ng, we don’t need .
Now inspection, hey don’t tell that ubsequent.
But we FDA as far as or ll those issues are done by the GMP with them, but we don’t know w sending anoth
So, when will
I think a yea further from u
And sir, can y doing.
So if y overall though
I think it’s too
So these are b
Biosimilar, Y
And you want
We have take trials and eve because, it ha
But sir, typica there would b projects come
I think there a crores.
So we come.
In curr crores higher.
This is the R&
Yes, yes, R&D
And sorry, si they’re doing
On subsidiary They’re a goo side.
So beca profitable com around GBP EBITDA mar IPCA Labo Fe when they will come.
And they don’t tell that when they will her reminders to them. l the last set of queries you had from the GMP department? ar back.
Final clearance has come six months back.
They don us, yes. you also give us, you mentioned about this biotech project, so you can give some details of what are the products, what kind ht process on this project? o early.
We will not like to talk of products right now, yes. biosimilar products or what… Yes. t to do it for the Indian market, you have a CDMO plan or… en the developed markets consultations from the regulators.
An erything is going to be in line with that.
Indian market, you ca as to be for global markets, yes. ally, the costs are very high.
So if you have to run clinical tria be significant increase in R&D investments over the next three, f e to clinics? are some kind of the -- each clinical trials may cost around INR e have five candidates in pipeline.
So overall cost would be go rent year also, our spend on biotech would be around INR 2 . &D expense, INR 20 crores, INR 25 crores?
D expense. ir, finally, if I can ask any update you can give on your key and any material update there you want to share on the subsidia y side, we have a company called Onyx in UK.
They are d od profitable company.
This year, there was a significant expan ause of that, I think their profitability have little come dow mpany overall.
And we expect that current year, they should 14 million to GBP 15 million kind of business with around 27 rgins in current year. oratories Limited ebruary 16, 2023 schedule.
We are n’t need anything ome capex you are of -- what is your nd all your clinical nnot make money als, will that mean four years as these 15 crores, INR 20 oing up in time to 20 crores, INR 25 subsidiaries, how aries? doing well in UK. sion there on their n, but they are a d be doing almost 7% kind of overall And then ther marketing kin doing well, an US, we have o company call could not do they have red do better.
Only concern once our FDA are -- they a company has and Vizag, th come in profi going on.
So these are t again, for FD there are a lot which is they gets cleared, t
Moderator · Conference Operator
We have the n
A Laboratories Limited · 3 Earnings Conference Call”
Just trying to currently at 1 material, som China, etceter levels?
See, overall g control.
It’s -- the promotion business with overall margi 1.5% on that year.
So becau And overall, o operating perf if things start currently toda right now bec contribute to t IPCA Labo Fe re is another company which we have is Trophic Wellness.
It nd of company where we have almost around 55% stake.
Tha nd they are also profitable.
As far as the Onyx business extens one small API manufacturing and contract research kind of com led [phisca 1:07:22], but because of these COVID issues and much on that.
So, but we have started getting now projects the duced their losses also significantly.
And hopefully, in time to c n we have is the US market is Bayshore, which is frontline, we A get cleared and they get to market, our products, and till suc are right now procuring products from third parties and then losses.
As far as the another company, associate company called hey have reduced their losses and I hope, I think, next year, t it.
The current developments, what we have on our product mix the broad number of subsidiaries that we have.
And Ramdev is DA approved site, and that site anyway, we are merging with o t of our APIs are now under filing from that site.
So then that w y have approved site and from there, we will then once our fo that also will be sourcing API from that site also. next question from the line of Prakash Agarwal from Axis Capit o understand the margin bridge.
I know you talked about it a 16%, guiding for 21%.
I understand top line will improve ma mething you’ve been saying that it’s not under your control as ra.
So how do you think you’ll regain to that 20%, 21%, which gross margins will improve because most of the portfolios are - 83% of portfolios are price controlled.
More or less, there will nal cost next year.
It will remain more or less at the same kind o h promotional costs now going up, it will also add to almost in levels in the business.
Gross margin levels itself will impro because KSM prices are soft, and this was a very unusual si use of that, the cost is higher. our capacity utilization with business is going up, will also incr formance and margin.
And once in the middle of the year, I thin t on commercial side, at least some recovery of expenditure ay, all costs are getting debited to P&L account and there are n cause of all validation exercise and filing is currently going. the margin. oratories Limited ebruary 16, 2023 t’s a nutraceutical at company is also sion further in the mpany in US, small d all our UK team ere.
And this year, come, they should e are awaiting that ch first time, there n selling.
So that d Kraps at Nellore that company will x and all currently s basically was for our operations and will be another site, ormulation facility tal. little, but you are arginally, but raw things come from h was pre-COVID e outside the price l be no increase in of -- increase your around 2% to the ve by around 1%, ituation in current ease to the overall nk overall, Dewas, will start because no revenue coming So that will also So all those fa a wage inflati all that, so th margin.
So a margin.
So if I unders back to 65% early-teens, y
Yes, more or
And secondly Formulation o etcetera.
And pharma comp normalized?
A teens in both,
Yes.
Even cur UK business b will not be th are also grow margin.
And API, sir?
API, we’ll sa and approval, 10% kind of g
And that high 10% or…
There are no n was required t
And early tee overall growth
I think it shou
Moderator · Conference Operator
Thank you.
T closing comm
A Laboratories Limited · 3 Earnings Conference Call”
Hi.
There is n call.
Thank yo IPCA Labo Fe actors and there are no more addition of people next year.
So it’ ion, whatever addition.
So with -- and with the people product hat will also contribute towards the better sales.
So it will also all those factors will add, will go back to that around 21% stood it correct, you are saying that 150 basis points from gro and top line being early-teens and then operating leverage cost ou will see 20%, 21% margin.
Is that correct understanding, sir? less, yes. y, if I see your emerging market business, ROW Generics as w overall, there in the last two, three years, there were a lot of in that’s why the growth has been a little volatile, not only for y panies.
Do you think the inventories and the demand, etc And a company like yourself could come back to at least early- in the overall Export Formulation market? rrent year, I think my European business is growing by around because of -- and the UK business will also grow from next yea here of at a year back of Bristol.
So UK will also grow very w wing good.
We should be able to -- and ROW market will grow ? ay that around next year, till the time, those capacities from De , only thereafter the business will start moving faster, but it sh growth. h base of the sartan etcetera is all behind us now.
So on this b now those kind of issues on all the impurities and everything el to be done, has been done. ens is good to modelling or we should look at mid-teens to h for the company? uld be almost around 12% to 13% kind of overall growth.
That was the last question.
I would now like to hand it over to th ments. nothing further to add, unless there are questions, I think we c ou, everyone, for participating in our Q3 FY ‘23 con call.
Thank oratories Limited ebruary 16, 2023 s only going to be tivity increase and add to the overall kind of EBITDA oss margin coming t being lower than ? well as the Export nventory stocking, you, but across the cetera, have been -teens, if not high- 20%.
It’s only the ar because the base ell.
Other markets faster with higher ewas are available hould have around base, we can grow se, whatever work high-teens as the he management for can close this con k you.
Moderator · Conference Operator
Thank you.
O Thank you for IPCA Labo Fe On behalf of DAM Capital Advisors Limited, that concludes r joining us and you may now disconnect your lines. oratories Limited ebruary 16, 2023 s this conference.